|
|
Start Date:12/15/2021
Start Time:8:30 AM EST
Duration:150 minutes
Abstract:
Highlighting the innovative work derived from its DARPin platform, Molecular Partners plans to share updates on its clinical oncology candidates, AMG 506 / MP0310 and MP0317, and its new triple-antigen targeted T-cell engager for AML, MP0533.
In addition, Molecular Partners’ management will describe the Company’s platform updates and strategy for portfolio growth and expansion.
If you're already registered for the Molecular Partners Oncology Day 2021 webcast, click below:
ALREADY REGISTERED?
Speakers
$-[WCSpeakerDisplayHTML]-$
|
|
Molecular Partners Oncology Day 2021
Registration Is Closed
|
|
|
|
|